Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations

Rhea-AI Summary

Propanc Biopharma (Nasdaq: PPCB) on Jan 27, 2026 filed a fourth provisional patent application in two months with IP Australia covering improved formulations of pancreatic proenzymes trypsinogen and chymotrypsinogen, the active components of its lead asset PRP. The filing targets stability, storage, freeze/thaw resilience and global transport challenges for proenzyme pharmaceutical compositions used in cancer and chronic diseases.

The company said these provisional filings, as they move to national phase entry, are expected to expand its patent estate from ~90 to >200 patents across compositions, formulations, treatment methods and indications, and support preparations for a Phase 1b first-in-human study in advanced cancer patients.

Positive

• Filed 4 provisional patents in two months
• Targets formulation stability, storage, and transport
• Plans to expand IP from ~90 to >200 patents
• Supports planned Phase 1b first-in-human study

Negative

• Applications are provisional and not yet granted
• National phase entry and patent grants are future events
• Phase 1b study is preparatory and not yet initiated

Argus Jan 27 session

+6.52% close to close Open Argus

Details

News Market Reaction – PPCB

In the Jan 27 session, PPCB gained 6.52%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +6.5% in the session following this news. A strong positive reaction aligns with the...

Analysis

The stock moved +6.5% in the session following this news. A strong positive reaction aligns with the company’s stated goal of building a broad IP moat around PRP, but past news showed limited price follow-through despite positive science updates. Investors may weigh today’s fourth provisional filing in two months against ongoing going-concern and listing risks disclosed in recent SEC filings. If enthusiasm faded after prior R&D milestones, sustained gains could depend on concrete clinical progress and financing visibility.

Key Figures

Recent provisional filings: 4 applications Planned patent portfolio: Over 200 patents Current IP portfolio: Approximately 90 patents +5 more

Recent provisional filings

4 applications

Fourth new provisional patent application filed in past two months with IP Australia

Planned patent portfolio

Over 200 patents

Company expects to more than double IP portfolio to over 200 patents worldwide

Current IP portfolio

Approximately 90 patents

Management references expansion from approximately 90 to over 200 patents

PRP formulation ratio

Trypsinogen + chymotrypsinogen

Lead asset PRP based on pancreatic proenzymes trypsinogen and chymotrypsinogen

Planned study phase

Phase 1b

PRP being prepared for a Phase 1b First-In-Human study in advanced cancer patients

IP horizon

Two decades

CEO states patents will secure leadership for the next two decades

Current share price

$0.279

Price before this news; trading far below 52-week high of $24

52-week range

$0.2404–$24

Shares sit 16.06% above low and 98.84% below high pre-announcement

Historical Context

5 past events · Latest: Jan 20

5 events

1. Jan 20

   Provisional patent filing

   24h Move

   -4.7%

   New provisional patent for synthetic Rec-PRP manufacturing methods with IP Australia.

2. Jan 15

   PRP overview & plans

   24h Move

   -17.1%

   Detailed PRP preclinical data, orphan drug status, financing context, and 2026 trial plans.

3. Jan 13

   Shareholder update

   24h Move

   -4.3%

   Outlined 2026 Phase 1b trial, financing history, IP portfolio size, and development roadmap.

4. Dec 22

   Peer-reviewed data

   24h Move

   -8.4%

   Published PRP data on PDAC fibroblasts and plans for a Phase 1b study in Q3 2026.

5. Dec 04

   Research collaboration

   24h Move

   -4.3%

   Joint research on mesenchymal drift, new PRP patent filing, and 2026 Phase 1b trial prep.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

proenzymes, trypsinogen, chymotrypsinogen, metastasis, +4 more

8 terms

proenzymes medical

"a novel therapeutic paradigm: using proenzymes to target and prevent metastasis"

Proenzymes are inactive precursors of enzymes that become functional only after a specific chemical change, often involving cutting part of the molecule, similar to removing a safety cover on a tool to make it usable. They matter to investors because drugs, diagnostics, and manufacturing processes that rely on proenzymes can have different effectiveness, safety profiles, storage needs, and production costs than products that use already-active enzymes, which can affect clinical outcomes, regulatory decisions, and commercial value.

trypsinogen medical

"formulations of the pancreatic proenzymes, trypsinogen and chymotrypsinogen— the active components"

Trypsinogen is an inactive protein produced by the pancreas that becomes the digestive enzyme trypsin when activated in the gut; think of it as a tool stored safely until it's switched on to do its job. It matters to investors because abnormal levels or malfunction can signal pancreatic disease, drive demand for diagnostics or treatments, and influence the regulatory and commercial prospects of drugs, enzyme therapies, or related medical tests.

chymotrypsinogen medical

"formulations of the pancreatic proenzymes, trypsinogen and chymotrypsinogen— the active components"

An inactive protein precursor that becomes the active digestive enzyme chymotrypsin when triggered in the body, chymotrypsinogen is like a tool with a safety cover that is removed only where and when it’s needed. Investors should care because it appears in biotech and pharmaceutical contexts—as a manufacturing material, potential contaminant, assay reagent, or drug target—so its presence or handling can affect product development, regulatory reviews, and commercial risk.

metastasis medical

"using proenzymes to target and prevent metastasis from solid tumors — particularly"

Metastasis is the process by which cancer cells break away from a primary tumor and travel to other parts of the body, where they form new tumors — like seeds carried by wind taking root in distant soil. It matters to investors because metastatic disease often requires more complex, longer-term treatments, drives larger market demand for advanced therapies, and strongly influences clinical trial design, regulatory decisions, and a drug’s commercial value.

cancer stem cells medical

"designed to selectively attack cancer stem cells and circulating tumor cells while"

Cells within a tumor that behave like seeds: they can regenerate the cancer, survive treatments, and drive relapse and spread. For investors, therapies that effectively target these cells are important because they promise longer-lasting cures and lower recurrence rates, which can increase the commercial value of a drug or change the outlook for companies developing cancer treatments.

circulating tumor cells medical

"selectively attack cancer stem cells and circulating tumor cells while sparing"

Circulating tumor cells are cancer cells that break away from a tumor and travel in the bloodstream, detectable through a blood test. Investors care because their presence and number can act like a real-time signal — similar to footprints showing where a person has been — revealing disease progression, response to treatment, or risk of metastasis, which influences the market value of diagnostics, therapies and clinical trial outcomes.

phase 1b medical

"propel our lead asset, PRP, into a landmark Phase 1b First-In-Human study"

"Phase 1b" is an early stage in testing a new medical treatment or vaccine, where it is given to a small group of people to evaluate its safety and determine the right dose. For investors, this phase signals progress in development, indicating the treatment is advancing through initial safety checks, which can influence expectations for future success and potential market impact.

first-in-human medical

"PRP, into a landmark Phase 1b First-In-Human study in advanced cancer patients"

A first-in-human study is the initial test of a new drug, medical device, or therapy in people to check safety, side effects and appropriate dosing. It matters to investors because it marks a major development milestone: successful early human testing can reduce scientific and regulatory uncertainty, much like moving a prototype from the workshop to a real-world test drive, and often affects a company’s valuation and funding prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Key Milestone Builds Toward Doubling Patent Portfolio to Over 200 Worldwide – Positioning Propanc as a Long-Term Leader in Metastatic Cancer Prevention

MELBOURNE, Australia, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced the filing of its fourth new provisional patent application in the past two months with IP Australia. This latest application focuses on innovative formulations of the pancreatic proenzymes, trypsinogen and chymotrypsinogen— the active components in Propanc’s lead asset, PRP — addressing critical challenges in stability, storage, freeze/thaw cycling, and global transport. These advancements overcome longstanding barriers in developing viable pharmaceutical compositions of these proenzymes for biomedical applications, including cancer and other chronic diseases.

“Filing four provisional patent applications in such a short timeframe underscores our relentless drive to protect and expand our groundbreaking proenzyme technology,” said Mr. James Nathanielsz, Propanc’s Chief Executive Officer. “As these applications advance to national phase entry across major global markets, we expect to more than double our IP portfolio — from approximately 90 to over 200 patents — covering compositions, formulations, treatment methods, and new therapeutic indications.”

This rapid IP expansion reinforces Propanc’s commanding position in a novel therapeutic paradigm: using proenzymes to target and prevent metastasis from solid tumors — particularly aggressive, poorly differentiated cancers where options remain limited and standard treatments often carry severe side effects.

“These patents applications will secure our leadership for the next two decades in a field with enormous unmet need,” Mr. Nathanielsz continued. “We’re building an unassailable foundation to propel our lead asset, PRP, into a landmark Phase 1b First-In-Human study in advanced cancer patients. Preparations are advancing rapidly, and we anticipate further exciting updates on our clinical pathway and broader pipeline in the near term.”

Propanc’s PRP is a proprietary intravenous formulation designed to selectively attack cancer stem cells and circulating tumor cells while sparing healthy tissue — offering potential as a long-term therapy to halt recurrence and metastasis without the toxicity of conventional chemotherapy or radiation.

About Propanc Biopharma, Inc.

Propanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to preventing cancer recurrence and metastasis by targeting and eradicating cancer stem cells through proenzyme activation. The Company’s lead product candidate, PRP, is designed to address the underlying drivers of cancer proliferation and spread.

More information: www.propanc.com

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors, made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company’s control. Forward-looking statements are not guarantees of future actions or performance. Actual results may differ materially from those in the forward-looking statements because of several factors, including, without limitation, risks and uncertainties related to market conditions, as well as those risks described under “Risk Factors” in the prospectus related to the proposed offering and those described in the Company’s filings with the SEC. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.

Company:
Propanc Biopharma, Inc.
James Nathanielsz

+61-3-9882-0780
info@propanc.com

Investor Contact:
irteam@propanc.com

FAQ

What did Propanc (PPCB) announce on January 27, 2026 about patents?

Propanc filed a fourth provisional patent application in two months with IP Australia covering proenzyme formulations.

How will the new PPCB provisional filings affect the company’s patent count?

The company said advancing applications to national phase could expand its portfolio from ~90 to over 200 patents.

What formulation issues do the new PPCB patents address?

They focus on stability, storage, freeze/thaw resilience, and global transport of trypsinogen and chymotrypsinogen.

Does the Propanc announcement include clinical plans for PRP (PPCB)?

Yes; the company said it is preparing for a Phase 1b first-in-human study in advanced cancer patients.

Are the new PPCB patents already enforceable worldwide?

No; the filings are provisional and must progress to national phase and grant to create enforceable rights.